Amgen
 |
|
Amgen headquarters in Thousand Oaks, California
|
|
|
Formerly called
|
Applied Molecular Genetics (1980–1983) |
|---|---|
| Public | |
| Traded as |
NASDAQ: AMGN NASDAQ-100 Component S&P 100 Component S&P 500 Component : 4332 |
| Industry | Biotechnology |
| Founded | 1980 |
| Headquarters | Thousand Oaks, California, U.S. |
|
Key people
|
Robert A. Bradway (Chairman, President, and CEO) |
| Products | Epogen, Aranesp, Kineret, Enbrel, Neulasta, Neupogen, Nplate, Vectibix, Prolia, Xgeva, and Sensipar/Mimpara. |
| Revenue |
 US$21.66 billion (2015)
|
|
US$8.47 billion (2015)
|
|
|
US$6.94 billion (2015) |
|
| Total assets |
US$71.45 billion (2015) |
| Total equity |
US$28.08 billion (2015) |
|
Number of employees
|
17,900 (December 2015) |
| Website | www |
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988, followed by Kevin W. Sharer in 2000. Robert A. Bradway became Amgen’s president and chief executive officer in May 2012 following Sharer's retirement.
...
Wikipedia